GHRS

NASDAQ

GH Research PLC

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2021

News25/Ratings12

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.

News · 26 weeks30+13%

2025-10-262026-04-19

Mix1990d

Insider8(42%)
Other7(37%)
SEC Filings4(21%)

Latest news

25 items

3dPR
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today issued a statement welcoming the White House Executive Order, signed on April 18, 2026, to accelerate medical treatments for serious mental illness, including innovative psychedelic medical treatments (the Executive Order). The Executive Order directs coordinated federal action to accelerate the development of, and expand patient access to, innovative therapies for serious mental illness. GH Research continues to advance GH001, its proprietary inhaled mebufotenin
6dINSIDER
SEC Form 3 filed by new insider Moore Duncan
3 - GH Research PLC (0001855129) (Issuer)
21dINSIDER
SEC Form 3 filed by new insider Cameron Aaron Luke
3 - GH Research PLC (0001855129) (Issuer)
21dINSIDER
SEC Form 3 filed by new insider Hanley Dermot John
3 - GH Research PLC (0001855129) (Issuer)
21dINSIDER
SEC Form 3 filed by new insider Halle Magnus Clemensen
3 - GH Research PLC (0001855129) (Issuer)
21dINSIDER
SEC Form 3 filed by new insider Forer Michael
3 - GH Research PLC (0001855129) (Issuer)
21dINSIDER
SEC Form 3 filed by new insider Valcheva Velichka
3 - GH Research PLC (0001855129) (Issuer)
21dINSIDER
SEC Form 3 filed by new insider Ryan Julie
3 - GH Research PLC (0001855129) (Issuer)
22dINSIDER
SEC Form 3 filed by new insider Schonharting Florian
3 - GH Research PLC (0001855129) (Issuer)
29dSEC
SEC Form 6-K filed by GH Research PLC
6-K - GH Research PLC (0001855129) (Filer)
29dPR
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is independent of prior antidepressant treatment failures DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced two peer-reviewed publications from its Phase 2b clinical program of GH001 in treatment-resistant depression (TRD): the primary trial results in JAMA Psychiatry, and a new analysis demonstrating that eff
38dSEC
SEC Form 6-K filed by GH Research PLC
6-K - GH Research PLC (0001855129) (Filer)
45dPR
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
Issued on behalf of Cybin D/B/A Helus PharmaUSANewsGroup.com News CommentaryVANCOUVER, BC, March 9, 2026 /CNW/ -- The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate1. The Drug Enforcement Administration raised its 2026 production quotas for controlled research compounds by 67%, reflecting expanding clinical trial activity across the therapeutics landscape2. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), a
49dSEC
SEC Form S-8 filed by GH Research PLC
S-8 - GH Research PLC (0001855129) (Filer)
49dSEC
SEC Form 20-F filed by GH Research PLC
20-F - GH Research PLC (0001855129) (Filer)
49dSEC
SEC Form 6-K filed by GH Research PLC
6-K - GH Research PLC (0001855129) (Filer)
49dPR
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congressesGH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCash, cash equivalents and marketable securities of $280.7 million as of December 31, 2025 DUBLIN, Ireland, March 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2025, and provided a business update. Business Update In 2025, the Company completed its Phase 2b trial of GH001
55dPR
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ:HELP), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), GH Research (NASDAQ:GHRS), and LB Pharmaceuticals (NASDAQ:LBRX).
65dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by GH Research PLC
SCHEDULE 13G/A - GH Research PLC (0001855129) (Subject)
91dSEC
SEC Form 6-K filed by GH Research PLC
6-K - GH Research PLC (0001855129) (Filer)
98dSEC
SEC Form 6-K filed by GH Research PLC
6-K - GH Research PLC (0001855129) (Filer)
100dSEC
SEC Form 6-K filed by GH Research PLC
6-K - GH Research PLC (0001855129) (Filer)
105dSEC
SEC Form 6-K filed by GH Research PLC
6-K - GH Research PLC (0001855129) (Filer)
108dSEC
SEC Form 6-K filed by GH Research PLC
6-K - GH Research PLC (0001855129) (Filer)
108dPR
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for 2026 DUBLIN, Jan. 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug Application (IND) for GH001. This clearance enables U.S. subject enrollment and progresses the company toward alignment of its development ac